SCHEMBL5715001

SCHEMBL5715001

O=C(Oc1ccc(Cc2ccc(C(F)(F)F)cn2)cc1)N1CCN(Cc2cccnc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.52
EPAS1 Q99814 1/20 0.52
SLC6A5 Q9Y345 1/20 0.51
FAAH O00519 1/20 0.51
LIPE Q05469 6/20 0.47
TRPV1 Q8NER1 1/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 1/20 0.47
TRPA1 O75762 1/20 0.46
BCHE P06276 1/20 0.46
POLB P06746 2/20 0.45
LMNA P02545 1/20 0.45
NAMPT P43490 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714276 0.91 LIPE (0.46) HIF1AEPAS1SLC6A5FAAHLIPE
SCHEMBL6102857 0.91 HIF1A (0.59) HIF1AEPAS1SLC6A5FAAHTRPV1
SCHEMBL5714459 0.90 LIPE (0.45) HIF1AEPAS1SLC6A5FAAHLIPE
SCHEMBL5714719 0.88 LIPE (0.48) FAAHLIPETRPV1TRPA1BCHE
SCHEMBL5650038 0.86 LIPE (0.66) HIF1AEPAS1SLC6A5FAAHLIPE
SCHEMBL5715397 0.86 SCN9A (0.53) LIPETRPV1KDM4EALDH1A1TRPA1
SCHEMBL5714738 0.86 KDM4E (0.58) KDM4EALDH1A1POLBLMNA
SCHEMBL5714399 0.86 LIPE (0.47) LIPETRPV1TRPA1BCHE
SCHEMBL5715320 0.85 KDM4E (0.51) KDM4EALDH1A1POLBLMNA
SCHEMBL5715259 0.83 LIPE (0.48) HIF1AEPAS1LIPETRPV1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL HIF1A 2832/4885EPAS1 631/4885SLC6A5 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.